Pegasystems Inc - PEGA - reported that its GAAP net income for 2011 was $10.1 million, compared to GAAP net loss of $5.9 million for 2010. QLT Inc - QLTI - announced positive preliminary results from its Phase 1b trial of QLT091001 in subjects With Retinitis Pigmentosa Due to retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase Mutations. Tekmira Pharmaceuticals Corp - TKMR - reported that it is adding a new RNAi therapeutic targeting ALDH2 for the treatment of alcohol-dependence to its product pipeline. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

• Added by: karmastock
• Date added: 01/03/12
• Video Duration: 01:15
• Category: News
• Number of views:360
• Tags: retinol acyltransferase Mutations, Retinitis Pigmentosa, RNAi therapeutic, Pegasystems, QLT Inc, Tekmira, PEGA, QLTI, TKMR, Nasdaq:PEGA, Nasdaq:TKMR, Nasdaq:QLTI (PEGA, TKMR, QLTI) CRWENewswire Stocks In Action



Post a Comment

To add a comment, please fill out the box below and click on the submit button. Comment:

There are currently no comments for this video